Aleix Prat
机构：University of Padua, Breast Cancer Research Foundation, Instituto Oncológico Dr. Rosell, Istituto Oncologico Veneto, Center for Cancer and Blood Disorders, Hospital Quirónsalud Barcelona, Hospital Clínic de Barcelona, Oryzon Genomics (Spain), Istituti di Ricovero e Cura a Carattere Scientifico, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona · ORCID：0000-0001-8686-0236
发表论文 25 篇 · 总被引 460 次 · h-index 8
代表论文
- Current and Future Management of HER2-Positive Metastatic Breast Cancer (2021 · JCO Oncology Practice · 被引 189)
- Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer (2024 · JAMA Oncology · 被引 84)
- Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer (2025 · New England Journal of Medicine · 被引 61)
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT (2024 · Journal of Clinical Oncology · 被引 43)
- HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis (2025 · The Lancet Oncology · 被引 23)
- Hormone receptor-positive early breast cancer in young women: A comprehensive review (2024 · Cancer Treatment Reviews · 被引 18)